Literature DB >> 27466294

Novel and Recurrent ACADS Mutations and Clinical Manifestations Observed in Korean Patients with Short-chain Acyl-coenzyme a Dehydrogenase Deficiency.

Yoo-Mi Kim1, Chong-Kun Cheon2, Kyung-Hee Park3, SungWon Park4, Gu-Hwan Kim5, Han-Wook Yoo5, Kyung-A Lee6, Jung Min Ko7.   

Abstract

Short-chain acyl-CoA dehydrogenase (SCAD) catalyzes the first step in mitochondrial short-chain β-oxidation, and its deficiency is caused by mutations in the ACADS We sought to investigate the spectrum ACADS mutations and associated clinical manifestations in Korean patients with SCAD deficiency. The study included ten patients with SCAD deficiency from 8 unrelated families as diagnosed by biochemical profile and mutation analyses. Clinical features, biochemical data, growth, and neurodevelopmental state were reviewed retrospectively. Eight patients were found during newborn screening, and two were diagnosed by family screening. During follow-up ranging from 2 months to 4.5 years, no hypoglycemic event was noted, and the development and growth of the patients were normal, except in two siblings. One exhibited hypotonia and gross motor delay, while one girl showed cyclic vomiting until the age of two years. We identified seven different mutations of ACADS Of these, p.E344G was the most frequent mutation with an allele frequency of 50%, followed by p.P55L with 18.8%. p.G108D and four novel mutations were identified: p.L93I, p.E228K, p.P377L, and p.R386H. Korean patients with SCAD deficiency showed heterogenous clinical features and ACADS genotype. Our data contributes to a better understanding of the distinct molecular genetic characteristics and clinical manifestations of SCAD deficiency.
© 2016 by the Association of Clinical Scientists, Inc.

Entities:  

Keywords:  ACADS; Fatty acid beta-oxidation; Newborn screening test; Short-chain acyl-CoA dehydrogenase deficiency

Mesh:

Substances:

Year:  2016        PMID: 27466294

Source DB:  PubMed          Journal:  Ann Clin Lab Sci        ISSN: 0091-7370            Impact factor:   1.256


  4 in total

1.  Targeted Therapies for Metabolic Myopathies Related to Glycogen Storage and Lipid Metabolism: a Systematic Review and Steps Towards a 'Treatabolome'.

Authors:  A Manta; S Spendiff; H Lochmüller; R Thompson
Journal:  J Neuromuscul Dis       Date:  2021

2.  A New Integrated Newborn Screening Workflow Can Provide a Shortcut to Differential Diagnosis and Confirmation of Inherited Metabolic Diseases.

Authors:  Jung Min Ko; Kyung Sun Park; Yeeok Kang; Seong Hyeuk Nam; Yoonjung Kim; Inho Park; Hyun Wook Chae; Soon Min Lee; Kyung A Lee; Jong Won Kim
Journal:  Yonsei Med J       Date:  2018-07       Impact factor: 2.759

3.  ACADS acts as a potential methylation biomarker associated with the proliferation and metastasis of hepatocellular carcinomas.

Authors:  Diyu Chen; Xiaode Feng; Zhen Lv; Xiaofeng Xu; Yuejie Lu; Wenxuan Wu; Hao Wu; Hua Liu; Linping Cao; Sunyi Ye; Jianzhong Chen; Jian Wu
Journal:  Aging (Albany NY)       Date:  2019-10-25       Impact factor: 5.682

4.  Twenty Metabolic Genes Based Signature Predicts Survival of Glioma Patients.

Authors:  Wenfang Xu; Zhenhao Liu; He Ren; Xueqing Peng; Aoshen Wu; Duan Ma; Gang Liu; Lei Liu
Journal:  J Cancer       Date:  2020-01-01       Impact factor: 4.207

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.